. SMA is one of a number of neurological disorders associated with genes that have important roles in RNA metabolism (see Supplementary information S1 (box)). Although SMA is caused by reduced levels of a ubiquitously expressed protein, survival motor neuron (SMN), it affects only the lower motor neurons. Several other neurogenetic disorders are caused by mutations in ubiquitously expressed genes, including amyotrophic lateral sclerosis (caused by mutations in superoxide dismutase 1 (SOD1)) 7 , Huntington's disease (caused by an expanded CAG repeat in huntingtin (HTT)) 8 and several others [9] [10] [11] [12] . Therefore, understanding how SMN deficiency causes SMA could give us insight into the more general question of how a mutation in a ubiquitously expressed gene causes a neurological disease.
Two hypotheses have arisen to explain SMA. Reduction of SMN is proposed to affect pre-mRNA splicing of certain genes or to disrupt its function in axons, resulting in reduced levels of certain transcripts in the distal axon. Recent papers provide evidence for both hypotheses. Here we discuss the function of SMN, SMA genetics and insights gained from animal models of the disease. We consider the evidence for each theory, how the proposed changes might result in SMA and how strong evidence for the mechanism of SMA might be found. We aim in this article to provide a summary of the current debate in the field and to provoke critical discussion of each of the proposed disease mechanisms, so that experiments may be designed to resolve how deficiency of SMN causes SMA.
SMN function
SMN is a 38 kD protein found in the cytoplasm and nucleus of all cells [13] [14] [15] [16] [17] . An isoform of SMN comprising only the amino terminus (exons 1-3 and a part of intron 3) and found only in axons has also been reported 18 . However, this isoform is unlikely to have a role in SMA, as some patients with SMA carry missense mutations in exon 6 that would not alter this isoform's coding sequence 19 . SMN has been reported to bind to or associate with many proteins [20] [21] [22] [23] . However, it is difficult to determine which of these interactors form functional complexes with SMN. Four criteria are useful in discerning the most likely functional SMN complexes. First, reciprocal immunoprecipitation of the endogenous forms of the interacting proteins should be shown. Second, isolation of a complex containing SMN and the protein in question U small nuclear RNA (U snRNA). A small nuclear RNA that is rich in uridine.
Sm proteins
Proteins that were first found as antigens in a patient with systemic lupus erythematosus, and were named after the patient. Sm and Sm-like (LSm) proteins constitute a group of RNA-binding proteins that have a common three-dimensional stucture and form a heptameric or hexameric ring.
Complementation
The ability of two mutant alleles to interact to produce a normal or milder phenotype. In general, this occurs when the mutations that give rise to the phenotype occur in two different genes. However, allelic complementation arises when different mutations in the same gene interact to produce a functional complex.
Tudor domain
A conserved stretch of 50 amino acids, originally found in the Tudor protein of Drosophila melanogaster, that is often found in proteins with known roles in RNA metabolism.
RNA granules
Cytoplasmic deposits that contain RNA. These can also be found in axons and dendrites. RNA in these granules may be transported to the distal axon for localized protein translation in the growth cone.
from cells or tissues should be possible. Third, colocalization of SMN and the protein in question should be demonstrated. This colocalization may be only partial, that is, each protein may be found separately in other locations (in other words, only some of the immunofluorescent 'spots' may show overlap); however, where it occurs the overlap should be complete (that is, the spots for each protein should be on top of each other, rather than partially overlapping) to be considered as evidence for interaction 24 . Finally, the complex containing the SMN-interacting protein should show a functional deficit on SMN reduction. At present, only the SMN complex involved in small nuclear ribonucleoprotein (snRNP) assembly has met these criteria.
SMN in snRNP assembly. The best-characterized SMN complex is involved in snRNP assembly 20, [25] [26] [27] [28] [29] [30] [31] (FIG. 1) .
Certain snRNPs are crucial for the recognition of splice sites and the catalytic removal of introns from premRNA. snRNPs known to be assembled by SMN are composed of a U small nuclear RNA (snRNA) (u1, u2, u4, u5, u11 or u12) and, for those snRNPs involved in splicing, a heptameric ring of Sm proteins 25, 32 . Although Sm proteins can self-associate onto snRNA in vitro 32 , the SMN complex is required for this process in vivo 27, 28 . The SMN complex that performs this function in vertebrates consists of SMN, GeMiN2-8 and uNR-interacting protein (uNRiP, also known as STRAP), and the assembly reaction is ATP dependent [25] [26] [27] [33] [34] [35] (FIG. 1) . evidence to date indicates that SMN in this complex exists as an oligomer; such data include SMN's ability to self-oligomerize in vitro 36, 37 , the interaction of the products of tagged SMN constructs in transfected cells 38, 39 and the results of genetic complementation studies in vivo 40 (see below). Proteomic studies of a functional ATP-dependent SMN complex that determine the precise stoichiometry of the components are needed to further confirm the oligomeric nature of SMN, as well as the number of SMN monomers in the active SMN complex.
in snRNP assembly, Sm proteins first form a complex with the chloride conductance regulatory protein (piCln, also known as iClN), which is thought to prevent inappropriate binding of Sm proteins to RNA 22, [25] [26] [27] [28] [29] [30] 41 . piCln exists in a complex known as the protein arginine methyltransferase 5 (PRMT5) complex, or methylsome, which can methylate Sm proteins and transfer them to the SMN complex [41] [42] [43] [44] (FIG. 1) . The SMN complex then facilitates assembly of the Sm proteins onto the snRNA 22, [25] [26] [27] [28] [29] [30] 41, [45] [46] [47] . Although the basic mechanisms of snRNP assembly are well characterized, there are a number of outstanding issues on which there is not full agreement (see Supplementary information S2 (box)). The Tudor domain of SMN has been shown to bind arginine-and glycinerich domains (RG and RGG domains) of various proteins, such as the Sm proteins SmB, SmD1 and SmD3 48, 49 . once the Sm proteins are assembled onto the snRNA, the 7-methylguanosine (m 7 G) cap of the snRNA is hypermethylated to a trimethylguanosine (TMG) cap, and the whole SMN complex with the snRNA is transported into the nucleus 50 . in the nucleus, snRNPs are further matured for pre-mRNA splicing; however, SMN's role in these steps is poorly defined. lSm10 and lSm11 interact with Sm proteins to form a heptameric ring that binds the u7 snRNAs 55 . SMN is important for assembly of this ring on u7 RNA in vitro 55 . lSm2-8 proteins form a ring structure on the u6 snRNA, which is localized to the nucleus [52] [53] [54] . u6 snRNA levels do not seem to be altered in tissue from mice with SMA 40, 56 . However, specific assembly reactions to test SMN's importance in lSm assembly on u6 snRNPs have not been reported.
Does
The lSm1-7 protein ring is found in the cytoplasm [52] [53] [54] , and the lSm1-7 proteins have roles in mRNA decay 57 and stabilization 58 . Recently, the lSm1 and lSm4 proteins have been shown to be present in dendrites and certain axons, including spinal cord axons 59 . This axonal and dendritic RNP complex was associated with RNAs transported in axons and contained SMN 59 . Although SMN has yet to be shown to be important for lSm ring assembly, it is clear that both piCln 60 and SMN can bind lSm4 (ReFS 48, 49) , making it possible that the SMN complex is important for assembly of these rings on mRNA.
The Scd6 family is made up of conserved lSm proteins that are associated with RNA granules. The Caenorhabditis elegans and Drosophila melanogaster orthologues of Scd6 -car-1 and trailer hitch, respectively -also contain Sm-like domains, form a seven-membered ring that can bind RNA 61 and have a role in RNA localization 61, 62 . The vertebrate orthologue of trailer hitch, lSm14, assembles onto mRNAs and associates with decapping enzyme 1 (DCP1) and Me13B in distinct protein complexes that do not contain lSm1-8 in non-neuronal cells [63] [64] [65] . lSm1 and lSm4 have been reported in an RNP complex containing SMN in neuronal processes 59 , but whether this complex or other vertebrate axonal RNP complexes contains lSm14 is not known. No assay to examine the effect of reduced SMN on assembly of these lSm RNPs has been reported. However, as lSm proteins are important in RNA localization and contain domains that can bind SMN, we suggest that SMN reduction might affect the assembly of RNP complexes that are crucial for mRNA transport. Alternatively, SMN has been proposed [66] [67] [68] to function in a unique axonal complex with heterogeneous nuclear ribonucleoproteins Q and R (hnRNPQ/R) 66, 67 and Z DNA-binding proteins (ZBPs) 69 to affect transport of β-actin mRNA or other mRNAs that are yet to be identified. SMN has also been suggested to be important for the assembly of small nucleolar ribonucleoproteins (snoRNPs) 75, 76 , and knockdown of SMN alters the level of u3 small nucleolar RNA (snoRNA) 77 . in snoRNPs, the snoRNA acts as a guide for the modification (methylation or pseudouridylation) of ribosomal RNA, tRNA and snRNA 78 . it is therefore necessary to determine which RNP assembly reactions are dependent on SMN and which are crucial to the development of SMA.
Genetics of SMA in humans, two genes, SMN1 and SMN2, encode SMN. SMA is an autosomal recessive disorder caused by loss or mutation of the SMN1 gene and retention Survival motor neuron (SMN) functions in the cytoplasm to assemble Sm proteins onto the snRNAs to produce an active snRNP particle 20, 25, 26, 32 . a | In the cytoplasm, the seven Sm proteins bind to the chloride conductance regulatory protein (pICln) 42, 43 . In vitro studies show that pICIn first binds the Sm proteins as two separate complexes, with one complex including SmB and SmD3, and the other including SmD1 and SmD2 (ReF. 44) . The latter subsequently binds SmE, SmF and SmG 44 . The protein arginine methyltransferase 5 (PRMT5) complex and PRMT7 methylate the Sm proteins SmB, SmD1 and SmD3 (ReFS 42, 43, 158, 159) . Sm proteins are released from the pICln-PRMT5 complex, and they bind the SMN complex. b | The SMN complex is composed of SMN, GEMIN2-8 and UNR-interacting protein (UNRIP). SMN is shown as an oligomer as it has been found to self-associate, and it has been suggested that oligomerization is crucial for SMN function (see main text). The exact numbers of SMN monomers in an SMN complex is unknown (it has been suggested to be an octomer) 160 . The gemins are shown as single units for simplicity, as the exact stoichiometry of the SMN complex has not been determined. c | snRNA is transcribed in the nucleus and then binds the export proteins phosphorylated adaptor for RNA export (PHAX), cap-binding complex (CBC), exportin (XPO1) and Ras-related nuclear protein GTP (RAN), which transport it to the cytoplasm 25 . In vertebrates, the snRNA is brought into the Sm protein-bound SMN complex by binding to GEMIN5 (ReF. 46) . d | The SMN complex places the Sm proteins onto the snRNA 25, 44 . The 7-methylguanosine (m 7 G) cap of the snRNA is hypermethylated by trimethylguanosine synthetase 1 (TGS1) 25 , allowing the SMN complex with the snRNA to bind snurportin and importin, which mediates transport of the SMN complex with an assembled snRNP into the nucleus 25 . e | In the nucleus, the SMN complex and snRNPs localize to the Cajal body and the snRNPs undergo further maturation 78 . Depending on the cell type and developmental stage, SMN can localize as a separate body adjacent to the Cajal body [13] [14] [15] . scaRNP, Cajal body-specific RNP. 
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of SMN2 (ReFS 6, 79) (FIG. 2) . Chromosomes that lack both SMN1 and SMN2 can occur in SMA carriers, but homozygous loss of both genes has not been reported, presumably as a result of lethality 79 . indeed, mice have a single Smn gene, the loss of which results in early embryonic lethality 80 . loss of SMN2 but not SMN1 does occur in the human population and has no consequence 79 . Patients with SMA can be divided into five groups (0-iv) based on the severity of their clinical presentation 81 . The copy number of SMN2 is a major determinant of severity 5, 6, 79, 82, 83 . SMN1 and SMN2 are 99.9% identical 84 , have equivalent promoters 85, 86 and express RNA 6 and protein ubiquitously 87, 88 . The functional difference between the two genes is a C-T change in exon 7, which alters the amount of exon 7 that is incorporated in the final SMN transcript; most transcripts from SMN2 lack exon 7 (ReFS 6,84,89-92). The absence of exon 7 disrupts SMN's ability to oligomerize, leading to an unstable protein that is rapidly degraded 36, 37, 93, 94 . in essence, a single SMN2 gene produces considerably less SMN protein than an SMN1 gene 87, 88 (FIG. 2) . Thus, SMA is caused by low SMN protein levels rather than the complete loss of SMN 87, 88 . in 95% of SMA cases the SMN1 gene is absent 6, 79 . However, 5% of SMA cases have small mutations, such as small deletions, splice mutations and missense mutations, in SMN1 (ReF. 95) . These missense mutations can give us important insight into the function of SMN that is disrupted in SMA. it is important to consider the context in which these missense mutations occur. SMN2 is always present, so interactions between the mutant protein and the wild-type SMN protein produced by SMN2 could occur. 36, 37 . All missense mutations that cause a major disruption of SMN's ability to form oligomers can be classified as severe alleles as when they occur in patients with a limited SMN2 copy number (one or two) they result in a severe phenotype 36, 96 . When SMN fails to oligomerize it is rapidly degraded, resulting in low SMN levels 94 . indeed, it has been reported that SMN levels from a type i SMA patient with a mutation that disrupts oligomerization (Y272C) were similar to those of typical type i patients with complete loss of SMN1 (ReF. 87) . A second group of severe SMA missense mutations disrupt the binding of the Sm proteins to SMN, but the mutant proteins can oligomerize [96] [97] [98] [99] [100] [101] [102] [103] A number of mutated forms of SMN have been assayed for their ability to perform snRNP assembly in the presence of limiting amounts of wild-type SMN. All of the proteins assayed that contained severe mutations did not perform snRNP assembly, whereas those with mild missense mutations did 40, 47, 104 . So, SMN proteins containing mild missense mutations retain the ability to oligomerize with wild-type SMN and bind Sm proteins. our understanding of how these mutated proteins function has been further clarified by genetic complementation studies
, which showed that SMN functions as an oligomer and that proteins with mild missense mutations are not functional alone. Thus, in vitro assays for the effects of the missense alleles on SMN function should be performed in the presence of limiting amounts of wild-type SMN. and SMN2 have an identical structure and are 99.9% identical at the sequence level 84 . The essential difference between the two genes is a single-nucleotide change in exon 7 (C or T, as indicated). This single-nucleotide change affects the splicing of the gene, so most SMN transcripts from SMN2 lack exon 7, whereas those from SMN1 contain exon 7 (ReFS 76, 84, (89) (90) (91) (92) 121) . However, because SMN2 does produce some full-length SMN, it can be viewed as a gene with reduced function but not loss of function. The loss of the amino acids that are encoded by exon 7 results in the production of an SMN protein with severely decreased oligomerization efficiency and stability 36, 37, 93, 94 , and the SMN monomers are rapidly degraded 94 . In this way, loss of SMN1 results in reduced SMN levels in most tissues. The SMN oligomer is represented as an octomer based on gel filtration of SMN complexes formed in vitro 160 . b | A diagram of SMN showing the exons and domains. Exon 2B encodes a domain that is important in binding GEMIN2, as well as for selfassociation 161 . Both exon 2A and exon 2B are conserved. The K domain is rich in lysine (K-rich), and there is a Tudor domain in exon 3 that binds Sm proteins 97 and has homology to other Tudor domains. Exon 5 and part of exon 6 contain a proline-rich (P-rich) domain that may influence profilin binding 162 . The C-terminal domain of exon 6 contains the conserved YG box and is important for self-association 161, 163 . Part a is modified, with permission, from Models of SMA and the requirement for SMN SMN deficiency has been modelled in several organisms 80, [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] (TABLe 2) . All species used to model SMA have one SMN gene that is equivalent to SMN1. in all organisms, loss of SMN leads to lethality; however, the exact time point of lethality is determined by the levels of maternal SMN (SMN derived from the mother's SMN gene as opposed to the embryo's). in mice lacking SMN there is minimal maternal SMN, and death occurs early 80 . However, in egg-laying animals such as zebrafish (C.e.B, unpublished observations) and D. melanogaster death occurs later, when maternal SMN levels drop below a crucial point 111 . As would be expected, loss of SMN from a specific tissue in conditional Smn mutants results in the death of that tissue 114, 117, 118 . in transgenic mice, the genetic situation that occurs in SMA has been modelled by the introduction of SMN2 into mice lacking mouse SMN. When the SMN2 copy number is low (two), SMA mice develop, whereas a high SMN2 copy number (eight) results in normal mice 107, 108 . High neuronal expression of SMN driven by the prion promoter rescues motor neuron loss in SMA mice and extends their survival, even though high SMN levels are not restored in all tissues 119 . This suggests that two copies of SMN2 produce sufficient SMN for the normal function of most tissues, whereas motor neurons require higher levels of SMN, at least in mice 119 . Further experiments to determine the precise temporal and spatial requirement for high SMN levels are required. in conditional mouse mutants, or in species in which maternal SMN prevents embryonic lethality, it is likely that SMN levels could mimic levels that occur in SMA and might in turn model some aspects of the disease. However, it is difficult to distinguish these features from The SMNY272C mutation has been reported in all three types of spinal muscular atrophy (SMA), with the severity of the phenotype being dependent on the copy number of the SMN2 gene. This mutant SMN does not oligomerize efficiently and is rapidly turned over. +, low binding or activity; ++, moderate binding or activity; +++ high binding or activity; ND, not determined. those that are due to SMN levels that fall below what is required for most cells. it is therefore advisable to confirm observations made in these systems in animals in which reduced levels of wild-type SMN are found everywhere.
There often seem to be inconsistencies between results obtained in different model systems, but we urge caution in this interpretation. For example, in D. melanogaster, substantial rescue of SMN-deficient animals can be obtained by expressing SMN in muscle 111, 120 .
Box 1 | Allelic complementation of SMN missense mutations
Allelic complementation occurs when a protein encoded by two different alleles oligomerizes to form a functional unit with greater activity than homomers from either allele 156, 157 . This is directly relevant to the analysis of spinal muscular atrophy (SMA) mild missense mutations.
Transgenic mice that lack a functional survival motor neuron gene (Smn) but express two copies of human SMN2 (SMA mice) 107, 108 have low levels of small nuclear ribonucleoprotein (snRNP) assembly in spinal cord tissue. These mice have severe SMA and die at postnatal day 5 (see the figure, part b) 104, 108 . Expression of the SMNA2G 98 or SMNA111G 40 missense alleles in this background (part d) increases their survival and increases snRNP assembly activity 40, 98, 104 . However, neither allele expressed alone (without SMN2) can rescue Smn -/-mice (part c) 40, 98 . The expression of one copy of SMN2 alone cannot rescue embryonic lethality in Smn -/-mice 109 ; however, the additional expression of one SMNA111G allele can. Thus, the wild-type SMN produced by SMN2 interacts with SMNA111G to give a greater total function than the addition of an SMN2 gene (SMA mice contain two copies of SMN2 and die at postnatal day 5). This indicates that two SMN proteins form a heteromer with substantial function.
Although they cannot function in vivo by themselves, in the presence of limiting amounts of full length SMN, all mild SMA missense alleles assayed to date (part d) have substantial snRNP activity. This activity suggests that when small amounts of wild-type SMN from SMN2 are added to mild mutant SMN the resulting heteromers are functional 40 . High levels of expression of SMNA111G increase snRNP assembly in Smn -/-mice that contain one copy of SMN2 to a much greater extent than in mice that contain an additional SMN2 copy, suggesting that the SMN complex is a heteromer of multiple subunits (an oligomer).
Severe alleles such as SMNI116F can interact with wild-type SMN but, when assayed in culture, SMNI116F does not complement low levels of wild-type SMN to result in increased snRNP assembly (part g) 47 . Indeed, as they do not have a dominant negative effect in carrier patients, it would be predicted that when these alleles interact with SMN from SMN2 there will be no net increase or decrease in total activity.
Could two missense mutations interact to produce a functional SMN oligomer? Although this situation would not arise in patients, this experiment can provide insights into the contribution of different protein domains to SMN function. Clearly, SMNA2G and SMNA111G do not complement each other 40 . However, it would be interesting to determine whether these amino-terminal mutations can complement mild carboxy-terminal mutations, which reduce but do not eliminate the ability to bind full-length SMN (this possibility is shown in part e) 36, 96 . The ability to assay SMN's snRNP assembly activity in vitro 44 will allow analysis of both homomer and heteromer activity of SMN missense mutations. This can then be correlated with complementation analysis in vivo to understand both the in vitro and in vivo properties affected by SMN missense mutations. In all cases, knowledge of the stability and the levels of mutant proteins in patient-derived cell lines is useful in directing future studies and in interpreting the results. The figure shows the outcome of experiments carried out to date on allelic complementation of SMN missense alleles. The amount of SMN and its assembly activity are defined as none (-), low (+), moderate (+++) or high (++++); '?' indicates that an allele has not been tested experimentally.
in SMA mice, however, expression of SMN in muscle alone has little effect 119 . An examination of the drivers and mutants used in each case reveals two differences. in D. melanogaster the muscle driver used is expressed early in dividing mesodermal tissue, whereas in mice the actin promoter used drives SMN expression in postmitotic myofibres, but not in satellite cells or other premitotic mesodermal tissues 111, 119, 120 . Furthermore, in D. melanogaster functional SMN becomes depleted over time, whereas in SMA mice the human SMN2 transgene continues to produce SMN. Thus, in SMN-deficient D. melanogaster, the expression of SMN in a wide range of premitotic mesodermal tissues has a strong impact, but the effect of SMN expression in postmitotic muscle fibres is unknown. in SMA mice, expression of SMN in postmitotic muscle fibres has no phenotypic effect, and the impact of expression in the mesoderm is unknown.
invertebrates and non-mammalian vertebrates can be used to carry out experiments that cannot be done efficiently in mammals. We would advocate exploiting the strengths of each species. Genetic screens in C. elegans and D. melanogaster can be used to identify suppressors and genetic interactors 120 , which can then be tested in both zebrafish and SMA mice. To date, the genes identified by suppressor and synthetic lethal screens in D. melanogaster 120 (discussed below) have not been tested in vertebrate models. in zebrafish, it is easy to test a large number of DNA constructs transiently, a select number of which can be followed up in transgenic mice or zebrafish. it is also advisable to confirm results obtained in vitro in cultured cells with in vivo systems.
in mice, a range of phenotypes can be obtained by controlling the titre of SMN or by introducing additional transgenes 39, 107, 108, 114, [117] [118] [119] [120] [121] . The introduction of eight copies of SMN2 completely rescues SMA mice, two copies results in SMA mice that die at 5 days of age 107, 108 and one copy is embryonic lethal 109 . Furthermore, introduction of a transgene that expresses SMN lacking exon 7 (SMN∆7) in SMA mice gives mice that survive to 14 days of age 39 with specific motor defects 122 , and introduction of SMNA2G (with an Ala-Gly mutation at position 2) results in a mild SMA phenotype 98 . it is clear that small changes in SMN levels can have a strong impact on phenotype 119 .
Understanding the cause of SMA Two hypotheses have been put forward to explain the mechanism of SMA (FIG. 3) . The first suggests that the disrupted formation of snRNPs affects the splicing of a select group of genes that are important for the motor neuron circuitry 20, 25, 104 . The second suggests that SMN has a function in axons that is disrupted in SMA 20, 25, 67, 104, 113, 123, 124 . it is also possible that the two hypotheses are linked; that is, reduced snRNP assembly could influence the splicing of a gene that is important for axons. There is evidence for both hypotheses, but there is still no clear indication of which is correct or whether both apply. SMN in snRNP assembly. According to the first hypothesis, SMN reduction causes an alteration in snRNP assembly, which in turn alters the amount or profile of snRNPs and thus causes an alteration in splicing. What are these alterations, and how do they give rise to SMA? Assays have been developed to measure SMN's ability to assemble Sm proteins onto snRNA both in cells from SMA patients and in tissues from SMA mice 27, 33, 47, 56, 104, [125] [126] [127] . in mice, snRNP assembly levels change during development 126 . in addition, spinal cord extracts from mice with severe SMA at postnatal day 3 have low snRNP assembly activity. Mice with mild SMA have less snRNP assembly activity than normal or carrier mice, but they have considerably more activity than mice with severe SMA 104 . There is currently a complete correlation between the ability of an SMN protein complex to perform snRNP assembly and its ability to rescue SMA animals 40, 104 . However, the introduction of constructs that correct assembly function could affect both the assembly of Sm proteins onto snRNA and the assembly of other RNP complexes. it is therefore important to assay the formation of various RNP complexes to determine which are dependent on SMN. Moreover, snRNP assembly has not been assayed directly in motor neurons of SMA mice. Still, the ability of SMN to perform assembly of RNP complexes seems to be crucial in SMA.
in zebrafish, decreased levels of Smn causes motor axon defects 113 . A study has shown that reintroduction of assembled snRNPs can rescue these defects 128 , suggesting that snRNP assembly is the crucial pathway that affects motor axons when Smn levels are reduced. However, as indicated by the authors, 50% of the zebrafish scored in the snRNP rescue assay were morphologically defective (the authors reported slightly delayed development and a shortened and/or kinked body axis), and snRNP reintroduction also rescued these morphological defects (see the supplemental table in ReF. 128 ). Therefore, it is possible that the morphological defects give rise to abnormal motor axons owing to the alteration of the body muscles upon which these axons extend, bringing into question the link between snRNPs and motor axon defects 113, 129 . Knockdown of gemin 2 (also known as Sip1) or piCln was also reported to cause motor axon defects in zebrafish, again supporting a role for snRNP assembly in the effects of SMN knockdown 128 . However, studies that knocked down either Smn or gemin 2 in individual motor neurons, thereby excluding morphological defects, demonstrated that knockdown of gemin 2 did not cause motor axon defects, whereas knockdown of Smn did 113 . To resolve the question of whether disrupted snRNP assembly is crucial for motor axon defects, it will be necessary to ask whether addition of snRNPs suppresses motor axon abnormalities when Smn is knocked down only in motor neurons as opposed to the whole organism. Studies should then be extended to genetic models of SMA in zebrafish and mice to ensure that rescue of other SMA phenotypes, including lethality, occurs.
The motor axonal phenotype observed in Smnknockdown zebrafish can be corrected by reintroducing full-length human SMN mRNA, but not mutant constructs or SMN lacking exon 7 (ReF. 123) . it was reported that the SMN mutant SMNA111G, which can perform snRNP assembly 40, 47 , could not rescue zebrafish axons. By contrast, a version of SMN that lacked exon 7 but had the additional amino acids vDQNQKe, and was predicted to be unable to perform snRNP assembly 123 , was able to rescue axons 123 . This was taken as evidence against this pathway being crucial to axon function. However, we have subsequently obtained evidence that SMNA111G can correct SMA in mice and axon defects in zebrafish when expressed at high levels 40 . Figure 3 | Mechanisms proposed to explain how reduced sMN levels cause sMA. According to one hypothesis (left side), reduced survival motor neuron protein (SMN) levels result in reduced assembly of Sm proteins onto small nuclear RNA (snRNA). This unevenly alters the levels of specific endogenous small nuclear RNPs (snRNPs), such as those used to splice minor introns (particularly U11) from pre-mRNA 40, 56, 104 . It remains to be determined what the downstream target genes of the affected snRNPs are and how this specifically affects motor neuron function (indicated by '?'). The crucial target gene may be specific to the motor neuron system or may have a function of vital importance to motor neurons. LSm proteins 1 and 4 have been found in axons in a ribonucleoprotein (RNP) complex 59 . We therefore suggest a second hypothesis: that reduced SMN levels might affect the assembly of LSm proteins required for axonal transport of mRNA, leading to reduced expression of specific genes at the synapse. However, a functional biochemical assay linking reduced SMN levels to an alteration in the formation of the complex required for transport of mRNA is lacking (indicated by '?'). Whether other LSm proteins, such as LSm14, associate with this complex in neurons is not known. We have not indicated other potential or known SMN-dependent assembly pathways, such as assembly of U7 snRNA, as it is not clear how alteration of this pathway would give rise to spinal muscular atrophy (SMA). However, we cannot eliminate the possibility that other RNP assembly reactions are affected by reduced SMN levels. Last, it is possible to unite the two hypotheses in a model in which reduced snRNP assembly causes reduced splicing of a target gene that is crucial for transport of mRNA to the motor neuron synapse. TMG, trimethylguanosine cap.
Active zone
A portion of the presynaptic membrane that faces the postsynaptic density across the synaptic cleft. It constitutes the site of synaptic vesicle clustering, docking and neurotransmitter release.
Furthermore, it has not been possible to assay snRNP assembly in fish extracts, and it is not clear whether the vDQNQKe allele does or does not perform snRNP assembly in vivo.
What is the consequence of reduced snRNP assembly? one would predict a uniform reduction in the levels of all of the SMN-assembled snRNPs. However, there seem to be uneven changes in the snRNP profiles of tissues in SMA mice 56, 104 . Most notably, there was a preferential reduction of minor snRNPs, such as those containing u11 snRNA, in the spinal cord 40, 56, 104 . This would suggest that some of the approximately 700 genes that use the minor u12-and u11-dependent splicing pathway would be disrupted 104, 130, 131 . However, a clear demonstration of an SMN-dependent downstream target that has a functional alteration in splicing has not been reported.
Studies using both expression arrays and exon arrays have been undertaken to determine the effects of SMN reduction on downstream genes. However, clear changes that can be convincingly related to SMA or even SMN levels directly, as opposed to nonspecific secondary changes due to the disease state of the mouse, have not been obtained 56, [132] [133] [134] . For example, a recent study used exon arrays to define changes in SMA mice (SMN2 +/+ ; Smn -/-; SMN∆7 +/+ ). These mice, which have an average life expectancy of 13 days, were examined at 11 days, when they were rapidly declining in health. Many hundreds of genes were altered in 11-day-old SMA mice in various tissues including the spinal cord 56 . However, it is difficult to know which of these changes are due to low SMN levels as opposed to secondary changes that are due to the disease state of the mouse. indeed, kidney cytochrome p450 (Cy27b1), a protein known to respond to stress stimuli, had the largest change in expression in the SMA sample 135 . Furthermore, it is difficult to mechanistically relate these changes to an alteration in the minor splicing pathway. Although the list of altered transcripts contains genes with minor introns, it also features numerous genes that lack them. in addition, SMN itself was not listed as altered in all tissues. it is therefore hard to distinguish a splice or expression change due to stress from changes that are due to SMN depletion. Given that there are a number of factors secondary to SMN reduction that might explain these splicing changes, it is not yet possible to conclude that SMA is a pan-splicing disease rather than a disorder that affects splicing of specific targets that are important for motor neurons.
overall, expression changes in SMA samples remain ill-defined, and the targets of reduced snRNPs have not been identified convincingly. Studies using arrays with exon junction probes 136 and the use of younger animals with suitable controls will aid this approach. Furthermore, analysis of gene expression in motor neurons will be useful 134 , as will the implementation of expression comparison using the new deep-sequencing techniques 137 . Therefore, we conclude that snRNP assembly is altered in SMA, correlates with phenotype severity and leads to reduced levels of certain snRNPs. However, which target genes are specifically affected remains unknown.
A role for SMN in axons. SMN has been found in neuronal axons and growth cones in culture, in low abundance in a complex that does not contain Sm proteins 38, 66, 68, 74, 124 . Although it is relatively straightforward to detect SMN in the axons of cultured cells, SMN has not been convincingly detected in either axons or synapses in vivo by light microscopy in vertebrates 138 . This is due in part to the difficulty in distinguishing whether granules or spots lie in an axon as opposed to an adjacent cell. This question might be resolved by the use of specific neural preparations and electron microscopy. To confirm the localization of SMN in axons, the loss or reduction of punctate SMN staining in axons and growth cones should be observed in SMA animals or when SMN is knocked down.
The idea of a role for SMN in axons was strengthened by the finding that knockdown of Smn in zebrafish leads to specific motor neuron axonal defects, including truncated and/or branched axons 113 . However, as described above, it is unclear whether these defects result from the loss of snRNP assembly or some other function of SMN. Currently, no mutant form of SMN that clearly lacks snRNP assembly activity can correct SMA in animals or humans. There is a complete correlation between reduced ability to assemble Sm proteins onto snRNA and the severity of SMA 40, 104 . However, the reduced assembly of other RNP complexes, for example lSm proteins, onto mRNA could also correlate with severity of SMA, and this possibility has not been examined. it is therefore crucial to both define the RNP complexes that SMN assembles and determine whether they are disrupted in SMA.
Motor neurons cultured from SMA mice show a similar phenotype to zebrafish with reduced Smn levels, including short axons with small growth cones and reduced levels of β-actin mRNA transport to the growth cones 67 . This results in an altered distribution of the Ca v 2.2 Ca 2+ channel and corresponding electrophysiological alterations 139 . An alteration of Ca 2+ channel distribution at the neuromuscular junction (NMJ) might influence neurotransmitter release and the development of active zones, as seen in mice that lack laminin-β2 (ReFS 140, 141) . interestingly, SMA mice do show developmental abnormalities of the NMJ, with reduced arborization 39, [142] [143] [144] . However, reduced folds at the NMJ do not necessarily indicate a severely impaired NMJ and do not account for the severe phenotype seen in SMA. As both the Ca v 2.1 and Ca v 2.2 channels are important in the CNS synapses, it is currently unclear why motor neuron synapses and not CNS synapses are affected, if alteration in Ca 2+ channels is crucial to SMA. Patients with a deficiency of laminin-β2 do not demonstrate the classic fibre type grouping seen in type i SMA or the uniform atrophy seen in type 0 SMA and severe SMA mice 145, 146 . Furthermore, in patients that lack laminin-β2 there is a clear dysfunction of the CNS 146 . Thus, it remains unclear whether SMA can be explained by an alteration of Ca 2+ channel distribution at the distal axon. Recently it was reported that SMA mice with a quite severe phenotype show reduced release of neurotransmiter at the NMJ, which could relate to altered
Informational suppressor
A suppressor that will modify a phenotype in a non-genespecific manner. For example, overexpression of plastin 3 may encourage axon growth, thereby rescuing the phenotypes caused by SMN deficiency and those caused by mutations in other genes.
Ca
2+ channel function at the NMJ or altered input to the motor neuron 144 . Further studies in SMA mouse models and humans 147 are required to resolve question of what, specifically, is altered at the NMJ.
in support of a crucial role for β-actin in SMA, plastin 3, a protein that stabilizes filamentous actin 148, 149 , has recently been reported to be a modifier of SMA 150 . However, there were some inconsistencies. First, in one discordant family, plastin 3 was expressed at similar levels in both the affected and unaffected siblings, with the male sibling being more severely affected. Second, in male patients with two copies of SMN2, SMA was not modified by high plastin 3 expression 5, 151, 152 . The authors suggest that this discrepancy occurs because plastin 3 is a sex-linked modifier with incomplete penetrance. However, it is difficult to eliminate the possibility that the expression of plastin 3 is associated with, rather than the cause of, the modification of SMA. The possibility that a transcription factor activates or repress both the gene encoding plastin 3 (PLS3) and a modifying gene, such as SMN2, in the spinal cord cannot be ruled out.
SMN and plastin 3 are reported to form a complex 150 , but it is unclear whether SMN is associated with filamentous actin, as the required assays have not been done 148, 149 . How could PLS3 modify the SMA phenotype? The axonal defects that occur in cultured motor neurons from SMA mice or zebrafish with Smn knockdown can be rescued by overexpression of plastin 3 (ReF. 150 ). However, whether this is because plastin 3 encourages axon growth or whether its effect is specific to SMA is unknown. Actin filaments are also important in the nucleus 153 , and it will be necessary to consider whether snRNP assembly or splicing can be altered by plastin 3 expression. Plastin 3 will need to be expressed in mouse models of SMA to determine whether the lethality caused by SMA can be corrected. in mice with severe SMA, motor neurons grow at a normal rate and do not show axonal branching or misdirection , which live for 14 days) show both loss of occupation and partial occupation of synapses 39, 142, 154 . Motor neuron synapses that mature rapidly during development are more vulnerable than those synapses that mature more slowly 154 . in addition, the NMJs of SMA mice are generally immature, with abnormal development and poor terminal arborization [142] [143] [144] . in mice with mild SMA (SMN2 120 . The results discussed above support a role for SMN in the axon, but conclusive evidence that it is the axonal SMN complex that is critically disrupted in SMA is still lacking. Certain important facts are not known. What is the function of SMN that is directly affected in SMA axons and can it be assayed? Does disruption of snRNP assembly alter the splicing of a gene that is crucial to motor axons and NMJ function? in the case of an axonal function, do reduced SMN levels directly affect the assembly of complexes onto mRNA, leading to decreased mRNA transport to the distal axon? if so, which mRNAs besides β-actin are affected, and can this be detected in vivo? last, how might this disruption of RNA transport disrupt the lower motor neuron so specifically, when SMN is found in the axons of all neurons? in this regard, it is important to assay the affect of reduced SMN on the pathways that have been proposed to be involved in SMA both in vitro and in vivo.
Conclusion
it is currently unclear how reduced SMN levels cause SMA. This issue may be resolved by combining biochemical and genetic approaches. In vitro assembly assays of proteins carrying SMN missense mutations, in both homomeric and heteromeric complexes, combined with allelic complementation (BOX 1) can be used to discern which SMN function is critically affected in SMA. Suppression or modification of the SMA phenotype can give invaluable insight into which process is crucial in SMA. A directed suppression approach in which a specific RNP assembly reaction, such as snRNP assembly, is restored in SMA mice, resulting in correction, would provide strong evidence that snRNP assembly is the affected pathway. However, such a suppressor that can be easily studied in mice has yet to be identified. By contrast, non-directed suppressor and synthetic lethal screens can be readily performed in D. melanogaster and C. elegans. These screens ask what can suppress or enhance a specific phenotype without making assumptions about a particular pathway. Such a screen in D. melanogaster has indicated that the bone morphogenetic protein (BMP) signalling pathway is important in correction of the bouton phenotype, but it is unclear whether BMP is an informational suppressor or relatively specific to suppression of SMA phenotypes 120 . Additional screens, in particular using knockdown as opposed to more severe mutants, should provide further insight into SMN-dependent pathways. Desirable features of the suppressor include a strong suppressive function, an ability to suppress more than one SMN-linked phenotype, an ability to eliminate informational suppressors and the presence of more than one suppressor in a pathway. Furthermore, the ability to translate suppression into a vertebrate model will be important. However, useful information can be obtained without fulfilling all these criteria. The identification of plastin 3 as a potential modifier of SMA is of great interest, and experiments to demonstrate that plastin 3 does indeed suppress the SMA phenotype in mice are crucial. if it does, it will be important to determine whether its suppressive function acts in the distal axon or in the nucleus.
snRNP assembly is clearly altered in SMA, but are other SMN-dependent assembly reactions affected? importantly, what dictates the motor neuron specificity of this disease, and how motor neuron-specific is SMA? Detailed expression studies using arrays or sequencing technologies are clearly required, but it will be vital to distinguish a direct target from an indirect target. Presumably in the case of snRNPs there would be different degrees of splicing dysfunction in mice with different severities of SMA. it is tempting to speculate that reduced SMN affects either the splicing or the axonal transport of a limited number of target genes that are specific to motor neurons. indeed, altered splicing of a gene could in turn give rise to altered transport of mRNA. Restoration of expression of this defective gene(s) would be predicted to suppress the SMA phenotype, thus confirming that the gene is a target. Answers to these questions may also provide insights into other disorders, such as amyotrophic lateral sclerosis. We believe that careful use of genetics and biochemistry can dissect the immediate molecular targets of SMN deficiency and provide information on the crucial pathway involved in SMA.
